Merz Therapeutics Gains EU Approval for XEOMIN in Pediatric Spasticity
FRANKFURT AM MAIN, Germany — September 17, 2026 Merz Therapeutics announced that it has received European Union and European...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
FRANKFURT AM MAIN, Germany — September 17, 2026 Merz Therapeutics announced that it has received European Union and European...
INGELHEIM, Germany — September 17, 2026 Boehringer Ingelheim announced the launch of PED Essentials, a free online learning hub...
